Organofab Technologies, Inc
From regenerative medicine to organ replacement and cancer immunotherapy, incredible developments in medicine are poised to revolutionize patient care in the very near term - an improvement in quality of life that also represents a huge economic opportunity. Organofab™ technology will facilitate the integration of many new techniques and tools to not only enable but also evolve the tissue engineering field. We envision combining 3D bioprinting and advanced nanotechnology techniques with state of the art equipment in our novel patented infrastructure. At the point of care, this system will produce differentiated, patient-specific cell types in naturally consistent structures, modeled after the patient’s existing anatomy.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Organofab Technologies, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- FF
Fred Flitsch
Chief Operating Officer · General Business & Management
EmailPhone - RF
Robert Flitsch
Chief Technology Officer · Information Technology
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Organofab Technologies, Inc
2 distinct titles indexed · top 2 shown.
- 1chief operating officer
- 1chief technology officer
Sign up to unlock all 2 contacts at Organofab Technologies, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Organofab Technologies, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.